Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Pfizer
Astex Pharmaceuticals, Inc.
Northwestern University
AbbVie
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Baylor College of Medicine
LEO Pharma
University of North Carolina, Chapel Hill
Alliance for Clinical Trials in Oncology
Wake Forest University Health Sciences
Vanderbilt University Medical Center
Mayo Clinic
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Seagen Inc.
Seagen Inc.
AVEO Pharmaceuticals, Inc.
Asan Medical Center
Vanderbilt-Ingram Cancer Center
Mayo Clinic
University of California, San Francisco